UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2582) 2582
life sciences & biomedicine (2482) 2482
humans (2253) 2253
diabetes mellitus, type 2 - drug therapy (1339) 1339
male (1261) 1261
diabetes (1118) 1118
endocrinology & metabolism (1108) 1108
type 2 diabetes (1100) 1100
female (981) 981
hypoglycemic agents - therapeutic use (964) 964
glucagon (943) 943
animals (844) 844
middle aged (759) 759
glucose (709) 709
glucagon-like peptide 1 (680) 680
insulin (680) 680
peptides (633) 633
diabetes mellitus (612) 612
hypoglycemic agents - adverse effects (585) 585
glucagon-like peptide 1 - analogs & derivatives (556) 556
liraglutide (552) 552
adult (539) 539
pharmacology & pharmacy (491) 491
treatment outcome (489) 489
blood glucose - metabolism (463) 463
glucagon-like peptide 1 - therapeutic use (459) 459
aged (458) 458
hypoglycemic agents - administration & dosage (457) 457
diabetes mellitus, type 2 - blood (427) 427
obesity (409) 409
blood glucose - drug effects (375) 375
clinical trials (370) 370
glucagon-like peptide-1 receptor (361) 361
analysis (358) 358
dextrose (357) 357
abridged index medicus (351) 351
care and treatment (350) 350
glucagon-like peptide-1 (342) 342
glucagon-like peptide 1 - metabolism (334) 334
glucagon-like peptide-1 receptor - agonists (334) 334
hypoglycemic agents - pharmacology (329) 329
dipeptidyl-peptidase iv inhibitors - therapeutic use (325) 325
hypoglycemic agents (322) 322
internal medicine (321) 321
peptides - therapeutic use (321) 321
drug therapy (319) 319
glp-1 (319) 319
risk factors (319) 319
body weight (298) 298
research (298) 298
diabetes therapy (290) 290
insulin resistance (282) 282
medicine & public health (280) 280
double-blind method (279) 279
diabetes mellitus, type 2 - metabolism (273) 273
glucagon-like peptide 1 - blood (269) 269
exenatide (267) 267
receptors, glucagon - agonists (263) 263
general & internal medicine (261) 261
glucagon-like peptide 1 - adverse effects (259) 259
health aspects (251) 251
mice (248) 248
insulin - blood (247) 247
drug therapy, combination (245) 245
medicine, general & internal (244) 244
glucagon-like peptide 1 - administration & dosage (242) 242
diabetes mellitus, type 2 - complications (240) 240
venoms - therapeutic use (239) 239
rats (230) 230
hypoglycemia (226) 226
incretins - therapeutic use (223) 223
digestive, oral, and skin physiology (219) 219
rodents (218) 218
physiological aspects (217) 217
patients (216) 216
glycated hemoglobin a - metabolism (215) 215
type 2 diabetes mellitus (215) 215
insulin - metabolism (212) 212
hyperglycemia (206) 206
glucagon-like peptide 1 - agonists (203) 203
glucagon-like peptide 1 - pharmacology (195) 195
drug administration schedule (193) 193
studies (190) 190
endocrine system (187) 187
cardiovascular system & cardiology (182) 182
review (181) 181
glucose metabolism (180) 180
peptides - adverse effects (178) 178
body mass index (176) 176
metabolism (176) 176
dose-response relationship, drug (173) 173
randomized controlled trials as topic (172) 172
peptides - administration & dosage (171) 171
body weight - drug effects (169) 169
obesity - drug therapy (169) 169
glycosylated hemoglobin (168) 168
metformin - therapeutic use (165) 165
metformin (163) 163
blood glucose - analysis (161) 161
cardiovascular disease (161) 161
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3024) 3024
German (28) 28
Japanese (15) 15
Spanish (14) 14
French (8) 8
Danish (5) 5
Chinese (3) 3
Korean (3) 3
Portuguese (3) 3
Russian (3) 3
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Dutch (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 1935-5548, 08/2014, Volume 37, Issue 8, pp. 2159 - 2167
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 10/2014, Volume 384, Issue 9951, pp. 1349 - 1357
Journal Article